Healthcare -
Biotechnology - NASDAQ - US
$ 6.5
0.00154 %
$ 7.17 M
Market Cap
-0.12
P/E
1. INTRINSIC VALUE
Balance Sheet
Apollomics, Inc.
| Current Assets | 10.3 M |
| Cash & Short-Term Investments | 9.77 M |
| Receivables | 127 K |
| Other Current Assets | 374 K |
| Non-Current Assets | 2.83 M |
| Long-Term Investments | 0 |
| PP&E | 1.02 M |
| Other Non-Current Assets | 1.81 M |
| Current Liabilities | 7.4 M |
| Accounts Payable | 0 |
| Short-Term Debt | 233 K |
| Other Current Liabilities | 7.17 M |
| Non-Current Liabilities | 835 K |
| Long-Term Debt | 733 K |
| Other Non-Current Liabilities | 102 K |
EFFICIENCY
Earnings Waterfall
Apollomics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 42.3 M |
| Operating Income | -42.3 M |
| Other Expenses | 11.3 M |
| Net Income | -53.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Apollomics, Inc.
| Net Income | -53.6 M |
| Depreciation & Amortization | 361 K |
| Capital Expenditures | -24 K |
| Stock-Based Compensation | 10.9 M |
| Change in Working Capital | 1.04 M |
| Others | 13.6 M |
| Free Cash Flow | -28.8 M |
Wall Street Analysts Price Targets
Apollomics, Inc.
APLM has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
APLM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Apollomics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.
globenewswire.com
- 2 months ago
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co., Ltd., an affiliate of LaunXP Biomedical Co., Ltd. (TWO: 6876) (“LaunXP”), announced today that the parties have entered into an agreement for the development and commercialization in Asia (excluding mainland China, Hong Kong and Macau) (the “LaunXP Territory”) of vebreltinib, Apollomics' proprietary c-Met inhibitor, in combination with an EGFR inhibitor (“EGFRi”) for the treatment of NSCLC. The EGFRi class of targeted kinase inhibitors is currently a foundational targeted therapy for the treatment of NSCLC and other tumor types.
globenewswire.com
- 2 months ago
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan.
globenewswire.com
- 5 months ago
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on December 10, 2024, it received a notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Rule 5550(a)(2) (the “Bid Price Requirement”), and Nasdaq has determined to continue the listing of the Company's Class A ordinary shares (“Class A Ordinary Shares”) on the Nasdaq Capital Market under the symbol “APLM.”
globenewswire.com
- 6 months ago
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY.
globenewswire.com
- 9 months ago
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2024 ended June 30, 2024, and highlighted updates for its pipeline.
globenewswire.com
- 10 months ago
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions 43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions
globenewswire.com
- 10 months ago
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that it has granted the Company's request for a 180-day extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market. As previously disclosed, Apollomics had received a notice from Nasdaq on January 16, 2024 that it is not in compliance with the Bid Price Requirement (as defined below), because the closing bid price of the Company's Ordinary Shares was below $1.00 per share for 30 consecutive business days.
globenewswire.com
- 11 months ago
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need
globenewswire.com
- 11 months ago
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene
globenewswire.com
- 1 year ago
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer
globenewswire.com
- 1 year ago
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline.
globenewswire.com
- 1 year ago
8. Profile
Summary
Apollomics, Inc. APLM
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 7.17 M
Dividend Yield
0.00%
Description
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Contact
989 East Hillsdale Blvd, Foster City, CA, 94404
https://www.apollomicsinc.com
IPO
Date
Nov. 26, 2021
Employees
13
Officers
Dr. Sanjeev Redkar MBA, Ph.D.
Co-Founder & Executive Director
Dr. Matthew James Plunkett Ph.D.
Chief Financial Officer
Dr. Guo-Liang Yu Ph.D.
Co-Founder, Chief Executive Officer & Executive Chairman